New drug sweeps clean in HIV model.
"I've tested a variety of antivirals over the last several years, and such a response is extremely unusual," says Che-Chung Tsai of the University of Washington's Regional Primate Research Center near Seattle, who leads the team.
In its effect on the simian virus, PMPA seems to act as a more effective, less toxic version of the widely used AIDS drug AZT (zidovudine). The new drug may be most useful soon after exposure to the virus, the scientists suggest in the Nov. 17 Science. Tsai says the macaque research "forms a basis for future studies of the drug on HIV infections."
The simian virus provides the best model scientists have for HIV. Monkeys infected with SIV usually go on to develop an incurable, AIDS-like illness. They can also be infected with HIV but remain free of disease.
As retroviruses, both SIV and HIV carry their genetic material in the form of ribonucleic acid (RNA). They use their RNA as a template to form DNA, which then attaches itself to a host's genetic material. Retroviral drugs such as AZT disrupt this process by interfering with the enzyme that forges DNA subunits into a whole molecule. AZT acts as a bogus subunit, or analog, that ties up the enzyme.
But AZT has many drawbacks. Viruses frequently mutate and form a new enzyme that is unaffected by AZT, Tsai says. Moreover, many cells fail to treat AZT as a potential subunit. Even if they do, the drug doesn't last long inside cells. "[It] has a short half-life," says Tsai.
The new drug may overcome those problems. PMPA's structure ensures that cells will treat it as a subunit, and it stays within a cell far longer than AZT. "This long intracellular half-life may be the reason for the powerful antiviral effects of PMPA," Tsai says. So far, in test-tube studies of the drug's effectiveness against SIV, the researchers have seen no signs that the virus can mutate out of PMPA's hold.
In the animal experiments, the team gave 25 macaques daily doses of PMPA for a month, starting 48 hours before, 4 hours after, or 24 hours after giving the monkeys SIV injections. The investigators looked for laboratory and clinical evidence of SIV infection for more than a year but found none, even in lymph nodes.
Ten other macaques given SIV but not PMPA all became infected.
"We found no evidence that PMPA harms the animals," Tsai says, adding that they found no significant changes in blood chemistry or cells. AZT, on the other hand, causes many side effects at far lower doses.
"Such protection with no toxicity is unprecedented in the monkey model of AIDS," says Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases in Bethesda, MD. "It suggests a possible role for PMPA in preventing HIV in health care workers or others accidentally exposed."
The researchers have set their sights on using the new drug to eliminate HIV in babies born to infected mothers. "Some 70 percent of transmission occurs during labor," Tsai says. "We would love, one day, to be able to give this [drug] to newborns at risk," he adds. Tsai and other researchers are now considering how to study PMPA's effectiveness in blocking maternal SIV transmission in macaques.
Tsai's group plans to investigate how long after the introduction of SIV the drug can block the spread of the virus and will continue to monitor possible toxicity. They also expect that PMPA may eventually have an important role in combination therapies against established HIV infections.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 18, 1995|
|Previous Article:||State asks: is tamoxifen a carcinogen?|
|Next Article:||Explaining the moon's two-faced appearance.|